CDKN2C Gene - GeneCards | CDN2C Protein | CDN2C Antibody
WEBAug 5, 2024 · CDKN2C is a protein coding gene that encodes a cyclin-dependent kinase inhibitor that regulates cell cycle and cell growth. It is involved in various diseases, pathways and processes, and has several aliases, paralogs and orthologs.
CDKN2C - Wikipedia
WEBFunction. The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to interact with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression.
A genome-wide gain-of-function screen identifies CDKN2C as a ... - Nature
WEBJun 1, 2020 · CDKN2C is overexpressed in highly permissive cells and HBV-infected patients. Mechanistic studies show a role for CDKN2C in inducing cell cycle G1 arrest through inhibition of CDK4/6 associated...
CDKN2C cyclin dependent kinase inhibitor 2C [ (human)]
WEBCDKN2C gene deletion is associated with plasma cell post-transplantation lymphoproliferative disorders. The differences in p18 (INK4c)and p57 (Kip2)activities in chronic myeloid leukemia and normal stem cells suggest a different cell cycle regulation.
CDKN2C - My Cancer Genome
WEBCyclin-dependent kinase inhibitor 2C (CDKN2C, also known as p18) is a gene that encodes a protein that inhibits the activation of CDK 4 and CDK6. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as bone cancer, endometrial cancer, and intestinal cancer.
Clinical significance of cyclin-dependent kinase inhibitor 2C ...
WEBJun 24, 2022 · Cyclin-dependent kinase inhibitor 2C (CDKN2C) was identified to participate in the occurrence and development of multiple cancers; however, its roles in small cell lung carcinoma (SCLC) remain unclear. Methods. Differential expression analysis of CDKN2C between SCLC and non-SCLC were performed based on 937 samples from …
Immunomodulation by anticancer cell cycle inhibitors
WEBApr 28, 2020 · The clinical activity of CDK4/CDK6 inhibitors has largely been attributed to their capacity to selectively block malignant cells in the G1 phase of the cell cycle by inhibiting the...
Clinical significance of cyclin-dependent kinase inhibitor 2C ...
WEBJun 24, 2022 · This study identified upregulated CDKN2C expression and its clinical significance in SCLC and other multiple cancers, suggesting its potential usefulness as a biomarker in treating and differentiating cancers.
CDKN2C - an overview | ScienceDirect Topics
WEBCDKN2C (encoding p18), CDKN2D (p19), CDKN1C (p57), E2F7, RB1 (pRB) and RBL1 (p107) are upregulated by E2F during S phase, yet these genes are known to regulate cell growth negatively when overexpressed [36–39]. Their induction could, however, function to ensure orderly progression through the cell cycle.
CDKN2C cyclin dependent kinase inhibitor 2C [ Homo sapiens …
WEBJun 17, 2024 · Summary. The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to interact with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression.
- Some results have been removed